Literature DB >> 3501353

Polymyalgia rheumatica and giant cell arteritis: a 5-year epidemiologic and clinical study in Reggio Emilia, Italy.

C Salvarani1, P L Macchioni, P L Tartoni, F Rossi, R Baricchi, C Castri, F Chiaravalloti, I Portioli.   

Abstract

Among the population of Reggio Emilia, Italy, 56 patients with polymyalgia rheumatica (PR) and giant cell arteritis (GCA) were identified during the 5-year period 1981-85. The average annual incidence rates of PR and GCA were 12.8 and 8.8 respectively per 100,000 population aged 50 years or older. Forty-nine patients were followed up and the mean duration of follow-up was 32 months. All the patients received steroid therapy. We have evaluated the cumulative probability of requiring continued steroid therapy between patients with PR only, GCA only, and PR associated with GCA using life-table methods with permanent discontinuation of therapy as an end point. The different duration of steroid therapy between these 3 groups did not achieve statistical significance by the method of Lee and Desu. We identified a 5 variable discriminant function that correctly predicted whether the duration of therapy would be longer or shorter than 16 months (median duration of therapy) in 80% of our patients followed up for at least 24 months. The presence of synovitis in PR is also discussed.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3501353

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  18 in total

1.  HLA-DRB1 alleles associated with polymyalgia rheumatica in northern Italy: correlation with disease severity.

Authors:  C Salvarani; L Boiardi; V Mantovani; A Ranzi; F Cantini; I Olivieri; M Bragliani; E Collina; P Macchioni
Journal:  Ann Rheum Dis       Date:  1999-05       Impact factor: 19.103

Review 2.  Polymyalgia rheumatica and giant cell arteritis in older patients: diagnosis and pharmacological management.

Authors:  Jean Schmidt; Kenneth J Warrington
Journal:  Drugs Aging       Date:  2011-08-01       Impact factor: 3.923

3.  Epidemiology of biopsy proven giant cell arteritis in northwestern Spain: trend over an 18 year period.

Authors:  M A González-Gay; C Garcia-Porrua; M J Rivas; P Rodriguez-Ledo; J Llorca
Journal:  Ann Rheum Dis       Date:  2001-04       Impact factor: 19.103

Review 4.  Clinical diagnosis and management of large vessel vasculitis: giant cell arteritis.

Authors:  Soumya Chatterjee; Scott D Flamm; Carmela D Tan; E Rene Rodriguez
Journal:  Curr Cardiol Rep       Date:  2014-07       Impact factor: 2.931

Review 5.  Giant cell arteritis: a review.

Authors:  Pravin Patil; Niral Karia; Shaifali Jain; Bhaskar Dasgupta
Journal:  Eye Brain       Date:  2013-03-09

6.  Do steroids increase lymphoma risk? A case-control study of lymphoma risk in polymyalgia rheumatica/giant cell arteritis.

Authors:  J Askling; L Klareskog; H Hjalgrim; E Baecklund; M Björkholm; A Ekbom
Journal:  Ann Rheum Dis       Date:  2005-04-20       Impact factor: 19.103

Review 7.  The diagnosis and treatment of giant cell arteritis.

Authors:  Thomas Ness; Thorsten A Bley; Wolfgang A Schmidt; Peter Lamprecht
Journal:  Dtsch Arztebl Int       Date:  2013-05-24       Impact factor: 5.594

8.  Biopsy proven and biopsy negative temporal arteritis: differences in clinical spectrum at the onset of the disease. Groupe de Recherche sur l'Artérite à Cellules Géantes.

Authors:  P Duhaut; L Pinède; H Bornet; S Demolombe-Ragué; C Dumontet; J Ninet; R Loire; J Pasquier
Journal:  Ann Rheum Dis       Date:  1999-06       Impact factor: 19.103

Review 9.  [Polymyalgia rheumatica].

Authors:  C Duftner; C Dejaco; M Schirmer
Journal:  Internist (Berl)       Date:  2009-01       Impact factor: 0.743

10.  The HLA-DRB1 locus as a genetic component in giant cell arteritis. Mapping of a disease-linked sequence motif to the antigen binding site of the HLA-DR molecule.

Authors:  C M Weyand; K C Hicok; G G Hunder; J J Goronzy
Journal:  J Clin Invest       Date:  1992-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.